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background:   The Reveal LINQTM is a miniaturized insertable cardiac monitor (ICM) with wireless telemetry for remote monitoring 
patients with suspected arrhythmias.
Methods:  The Reveal LINQTM Usability study is a prospective, multicenter clinical trial assessing first-in-man usability of the new device, 
a new procedure, and overall monitoring system performance. We report on the procedural characteristics of 151 implants. Data were 
collected at baseline and through one month follow-up visits.
results:  The mean age was 57 ± 12 years; 33% were female. The primary indications for ICM implant were syncope (N=19), suspected 
AF (N=4), AF ablation monitoring (N=104), AF management (N=20), palpitations (N=3) or cryptogenic stroke (N=1). All patients were 
successfully inserted with the ICM. Ease of insertion procedure was rated easy or very easy for 94% of insertions. The majority of the 
patients (N=139; 92.1%) were implanted at the best recommended location, with most (N=123; 81.5%) incisions cranial to the device. 
Most implants were performed in the catheterization lab (N=130; 86.1%) and without active fixation (N=129; 85.4%). Procedures took 
place under local anesthesia (N=147; 97.4%) or general anesthesia (N=4; 2.6%). Antibiotics were administered prior to the procedure in 73 
(48.3%) patients. The device was implanted at an average depth of 8.0 ± 4.2mm. There was minimal to no incision site bleeding reported in 
144 (95.3%) patients and moderate bleeding reported in 7 (4.6%) patients. The closure methods at the completion of the procedure varied 
with sutures used in 64 (42.4%) procedures, steri-strips in 60 (39.7%), dermabond in 14 (9.3%) or a miscellaneous method in 13 (8.6%). 
R-wave amplitudes were 0.543 ± 0.295 mV at implant and 0.599 ± 0.314 mV at one month. In 147 patients with X-ray images available, no 
clinically significant device migration was observed. There was one serious procedure and device-related adverse event within one month 
of follow-up involving a skin perforation that resulted in device explant.
Conclusion:  The miniaturized Reveal LINQTM ICM supports arrhythmia detection with a simplified procedure, achieving stable sensing 
performance without device migration issues or safety risks.
